Mostly Sanguine Regulatory Outlook for Biotech, Healthcare Names
July 30, 2021 at 13:07 PM EDT
A change in leadership in the Oval Office often stirs talk about the regulatory environment for the healthcare sector. That talk is often elevated when one party controls the presidency and both houses of Congress, as is the case today. That doesn’t mean investors need to fret about exchange...